Core Cap Advisors, LLC Catalyst Pharmaceuticals, Inc. Transaction History
Core Cap Advisors, LLC
- $2.18 Billion
- Q1 2025
A detailed history of Core Cap Advisors, LLC transactions in Catalyst Pharmaceuticals, Inc. stock. As of the latest transaction made, Core Cap Advisors, LLC holds 34,242 shares of CPRX stock, worth $868,377. This represents 0.04% of its overall portfolio holdings.
Number of Shares
34,242
Previous 35,880
4.57%
Holding current value
$868,377
Previous $748,000
10.96%
% of portfolio
0.04%
Previous 0.04%
Shares
9 transactions
Others Institutions Holding CPRX
# of Institutions
389Shares Held
99.3MCall Options Held
37KPut Options Held
20.5K-
Black Rock Inc. New York, NY18.7MShares$474 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.5MShares$215 Million0.0% of portfolio
-
State Street Corp Boston, MA5.53MShares$140 Million0.01% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY3.42MShares$86.8 Million2.1% of portfolio
-
Goldman Sachs Group Inc New York, NY3.14MShares$79.5 Million0.01% of portfolio
About CATALYST PHARMACEUTICALS, INC.
- Ticker CPRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 102,820,000
- Market Cap $2.61B
- Description
- Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthe...